hAECs
PreclinicalBiologic
hAECs is one of 13 biologic programs targeting Hematopoietic Stem Cell Transplantation. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Hematopoietic Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Cyklokapron
JJ Molner
Phase 3
Fludara
SanofiPhase 2
Alkeran
AApotex Inc.
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Cyclophosphamide IV
AAssistance Publique - Hôpitaux de Paris
Phase 3
Interleukin 2
EEssen Biotech
Phase 1
IFN-γ Positive Selected T-Cells
UUniversity Hospital, Basel, Switzerland
Phase 2
Dose Extension
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 1
hAECs
TThe Second Affiliated Hospital of Chongqing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hematopoietic Stem Cell Transplantation1 trial
Ovarian Insufficiency1 trial
Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03207412·20 enrolled
Unspecified1 trial
Human Amniotic Epithelial Cells for Asherman's Syndrome
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 1·NCT03223454·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hAECs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details